Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3131)

  • STATUS
    Recruiting
  • End date
    Jan 28, 2025
  • participants needed
    466
  • sponsor
    Bausch Health Americas, Inc.
Updated on 28 April 2022
ascites
encephalopathy
liver disease
cirrhosis
screening procedures
rifaximin
conn
mini-mental status exam

Summary

Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in advanced liver cirrhosis, defined by the presence of medically controlled ascites.

Details
Condition Hepatic Encephalopathy
Treatment Placebo, Rifaximin SSD
Clinical Study IdentifierNCT05071716
SponsorBausch Health Americas, Inc.
Last Modified on28 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Participant has a diagnosis of advanced liver cirrhosis with medically controlled ascites (>30 days) not requiring therapeutic paracentesis (prophylactic variceal banding allowed if no history of previous variceal bleeding)
Participant has a Child-Pugh B Classification (score of 7 to 9 inclusive) without OHE and a Model End-Stage Liver Disease Sodium (MELD-Na) score of <15 at Visit 1
Participant has a Conn (West Haven Criteria) score of <2 without known neurologic, psychiatric or iatrogenically induced increase
Participant has a Mini-Mental State Examination (MMSE) score ≥ 24 and demonstrates no cognitive impairment upon exam at screening and baseline
Participant is at least 18 and ≤70 years of age
Females of childbearing (reproductive) potential must have a negative serum or urine pregnancy test at screening. All participants must agree to use 2 acceptable methods of contraception throughout their participation in the study
Participant must be able to independently read, fully understand and provide written informed consent on the Institutional Review Board (IRB)/Ethics Committee (EC) approved informed consent form (ICF) without additional support and provide authorization as appropriate per local privacy regulations

Exclusion Criteria

Participant has an active coronavirus disease 2019 (COVID 19) infection that is unresolved or, in the opinion of the investigator, may affect evaluation of the study drug or place the subject at undue risk
Participant has a history of anaphylaxis or hypersensitivity to rifaximin, rifampin, rifamycin antimicrobial agents, or any of the components of rifaximin
Participant has a history of drug-induced liver injury, drug rash with eosinophilia and systemic symptom (DRESS) syndrome
Participant has a history or current clinical suspicion of hepatopulmonary syndrome
Participant has a history of SBP, primary or secondary SBP prophylaxis, EVB, or AKI-HRS
Participant has a documented history of an OHE episode (Conn score ≥ 2) or has a history of rifaximin 550 mg and lactulose use for suspected OHE episode
Participant has either: a) no history of ascites -or- b) uncontrolled ascites
Participant has other non-controllable neurological or psychiatric conditions which may confound the assessment of cognitive function (e.g., dementia, schizophrenia, etc.)
Participants with focal neurological deficits due to a neurological event such as cerebrovascular accident
Participants with Wernicke's or Wernicke-Korsakoff encephalopathy
Participant has signs of alcohol use disorder, defined as Alcohol Use Disorders Identification Test (AUDIT-10) score of >7, within 6 months of signing the ICF
Participant has pseudomembranous colitis, abdominal abscess, or clinically significant strictures and fistulas of the gastrointestinal tract
Participant has epilepsy and experienced a seizure within 12 weeks prior to screening
Participant consumes more than moderate amounts of alcohol, defined as 1 standard drink per day for women and 2 standard drinks per day for men
Participant has a history of substance abuse < 6 months prior to signing the ICF and cannot refrain from substance abuse during the study period
Participant is currently taking narcotics, benzodiazepines, or psychoactive medicines which cannot be discontinued
Participant is currently taking an anticoagulant
Participant has been diagnosed with an uncontrolled infection < 4 weeks prior to screening
Participant has been diagnosed with an upper gastrointestinal bleed from non-variceal sources < 6 weeks prior to screening
Participant shows the presence of intestinal obstruction or has inflammatory bowel disease
Participant has undergone bariatric surgery or intestinal resection
Participant has a history of portal vein thrombosis, a history of a transjugular intrahepatic portosystemic shunt (TIPS) procedure, or plans to undergo a TIPS procedure
Participant has a history of shunt surgery or direct intrahepatic portocaval shunt (DIPS) procedure for portal hypertension or plans to undergo a DIPS procedure
Participant has a history of peritoneal dialysis
Participant has undergone prophylactic variceal banding within 2 weeks of screening or is scheduled to undergo prophylactic variceal banding during the study (Note: participants with previous prophylactic variceal banding will be allowed to participate in the study)
Participant has Type 1 or Type 2 diabetes that is not adequately controlled in the opinion of the investigator
Participant has severe co-morbid disease with a life expectancy < 1 year
Participant has active malignancy (except basal carcinoma of the skin), including active hepatocellular carcinoma (HCC) and/or a past history of HCC. Participants with resections or ablations of squamous cell carcinoma of the skin, or in situ carcinoma of the cervix, that occurred greater than 6 months prior to screening and are considered disease free are eligible for enrollment
Evidence of HCC or a lesion suspicious for HCC within 6 months on ultrasound or contrast multiphase magnetic resonance imaging (MRI) or computed tomography (CT). If this imaging is not available, or if alpha-fetoprotein (AFP) ≥ 20 ng/ml at screening, participants should undergo standard of care diagnostic procedures with their personal physician to rule out HCC during the screening period
Participant requires hemodialysis
Participant has any condition or circumstance that adversely affects the participant, could cause noncompliance with treatment or visits, may impact the interpretation of clinical data, could cause bias, or may otherwise contraindicate the participant's participation in the study
Participant used any investigational product or device within 30 days or 5 half-lives of the investigational product (whichever comes first) of providing consent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note